In 2023, the turnover of Biotechnology Research and Experimental Development in Norway stood at 800 million Euros. From 2024 to 2028, the forecasted turnover values are expected to grow steadily each year, starting at 866.2 million Euros in 2024, and reaching 1080.0 million Euros by 2028. Year-on-year, the turnover shows an average increase of approximately 7-8%, with a Compound Annual Growth Rate (CAGR) of around 6.2% over the five-year period.
The anticipated growth indicates a robust expansion of the biotechnology sector in Norway. Key trends to watch for in the future include advancements in personalized medicine, increased funding for biotech startups, and greater collaboration between academic institutions and commercial entities. Additionally, regulatory changes and global economic conditions could also impact the sector’s growth trajectory.
